SG11201702909QA - Stable protein solution formulation containing high concentration of an anti-vegf antibody - Google Patents

Stable protein solution formulation containing high concentration of an anti-vegf antibody

Info

Publication number
SG11201702909QA
SG11201702909QA SG11201702909QA SG11201702909QA SG11201702909QA SG 11201702909Q A SG11201702909Q A SG 11201702909QA SG 11201702909Q A SG11201702909Q A SG 11201702909QA SG 11201702909Q A SG11201702909Q A SG 11201702909QA SG 11201702909Q A SG11201702909Q A SG 11201702909QA
Authority
SG
Singapore
Prior art keywords
high concentration
protein solution
formulation containing
containing high
vegf antibody
Prior art date
Application number
SG11201702909QA
Other languages
English (en)
Inventor
Huixiang Zhang
Charles Boring
Alok Kulshreshtha
Yuhong Zeng
Li Wan
Laman Alani
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54697654&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201702909Q(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG11201702909QA publication Critical patent/SG11201702909QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
    • A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
    • A61B3/12—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Surgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11201702909QA 2014-11-07 2015-11-06 Stable protein solution formulation containing high concentration of an anti-vegf antibody SG11201702909QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462076770P 2014-11-07 2014-11-07
US201462088061P 2014-12-05 2014-12-05
PCT/US2015/059571 WO2016073915A1 (en) 2014-11-07 2015-11-06 Stable protein solution formulation containing high concentration of an anti-vegf antibody

Publications (1)

Publication Number Publication Date
SG11201702909QA true SG11201702909QA (en) 2017-05-30

Family

ID=54697654

Family Applications (3)

Application Number Title Priority Date Filing Date
SG11201702909QA SG11201702909QA (en) 2014-11-07 2015-11-06 Stable protein solution formulation containing high concentration of an anti-vegf antibody
SG10201913565RA SG10201913565RA (en) 2014-11-07 2015-11-06 Stable protein solution formulation containing high concentration of an anti-vegf antibody
SG11201702954XA SG11201702954XA (en) 2014-11-07 2015-11-06 Methods for treating ocular diseases

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG10201913565RA SG10201913565RA (en) 2014-11-07 2015-11-06 Stable protein solution formulation containing high concentration of an anti-vegf antibody
SG11201702954XA SG11201702954XA (en) 2014-11-07 2015-11-06 Methods for treating ocular diseases

Country Status (24)

Country Link
US (5) US10689438B2 (he)
EP (2) EP3215123A1 (he)
JP (5) JP6753848B2 (he)
KR (3) KR102588846B1 (he)
CN (3) CN107635580A (he)
AU (6) AU2015342815B2 (he)
BR (2) BR112017008093A2 (he)
CA (2) CA2966758A1 (he)
CL (2) CL2017001117A1 (he)
CO (1) CO2017004596A2 (he)
EA (1) EA201790989A1 (he)
EC (1) ECSP17034829A (he)
GT (1) GT201700096A (he)
IL (5) IL251642B (he)
MX (3) MX2017005875A (he)
MY (2) MY183807A (he)
NZ (1) NZ730821A (he)
PE (1) PE20170780A1 (he)
PH (2) PH12017500843A1 (he)
RU (1) RU2722643C2 (he)
SG (3) SG11201702909QA (he)
TN (1) TN2017000128A1 (he)
TW (4) TWI806150B (he)
WO (2) WO2016073915A1 (he)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110122881A (ko) 2006-04-07 2011-11-11 워너 칠콧 컴퍼니 엘엘씨 인간 단백질 타이로신 포스파타아제 베타(ｈｐｔｐ베타)에 결합하는 항체 및 그의 용도
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
TR201808591T4 (tr) 2008-06-25 2018-07-23 Esbatech Alcon Biomed Res Unit Bir evrensel bir antikor iskeleti kullanılarak tavşan antikorların insanlaştırılması.
BRPI0914319B8 (pt) 2008-06-25 2021-05-25 Esbatech Alcon Biomed Res Unit imunoligante que se liga especificamente ao tnf alfa humano e composição
JP5536113B2 (ja) 2009-07-06 2014-07-02 アケビア セラピューティクス インコーポレイテッド がん細胞の転移を予防するための化合物、組成物および方法
SG10201802789VA (en) 2011-01-13 2018-05-30 Regeneron Pharma Use of a vegf antagonist to treat angiogenic eye disorders
AU2012323856B2 (en) 2011-10-13 2017-05-25 EyePoint Pharmaceuticals, Inc. Methods for treating Vascular Leak Syndrome and cancer
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
JP6483148B2 (ja) 2014-03-14 2019-03-13 エアーピオ セラピューティクス インコーポレイテッド ＨＰＴＰ−β阻害剤
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
TWI806150B (zh) 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
RU2699544C2 (ru) 2015-01-28 2019-09-06 Пфайзер Инк. Стабильная водная композиция антитела против фактора роста эндотелия сосудов (VEGF)
US10633433B2 (en) 2015-01-28 2020-04-28 Prothena Biosciences Limited Anti-transthyretin antibodies
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
CN108290057A (zh) 2015-09-23 2018-07-17 爱尔皮奥治疗有限公司 用tie-2的激活剂治疗眼内压的方法
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
WO2018017714A1 (en) 2016-07-20 2018-01-25 Aerpio Therapeutics, Inc. HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
CN110248674B (zh) * 2016-09-07 2021-10-26 萨辛生命科学有限公司 针对vegf的合成抗体及其用途
US11692027B2 (en) 2016-09-28 2023-07-04 Board Of Regents, The University Of Texas System Antibody and protein therapeutic formulations and uses thereof
MY195529A (en) 2016-11-18 2023-01-30 Astellas Pharma Inc Novel Anti-Human MUC1 Antibody Fab Fragment
US11851659B2 (en) 2017-03-22 2023-12-26 Novartis Ag Compositions and methods for immunooncology
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
WO2018195912A1 (zh) * 2017-04-28 2018-11-01 苏州思坦维生物技术股份有限公司 一种眼用药物组合物及其用途
TWI795415B (zh) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
WO2019020777A1 (en) * 2017-07-26 2019-01-31 Formycon Ag LIQUID FORMULATION OF A VEGF ANTAGONIST
CU20200021A7 (es) 2017-10-06 2021-01-12 Prothena Biosciences Ltd Anticuerpos anti-transtiretina
BR112020010483A2 (pt) * 2017-11-29 2020-10-20 Prothena Biosciences Limited formulação liofilizada de um anticorpo monoclonal contra transtirretina
CN111699004A (zh) * 2018-02-06 2020-09-22 豪夫迈·罗氏有限公司 眼科疾病的治疗
EP3765083A1 (en) * 2018-03-16 2021-01-20 Novartis Ag Methods for treating ocular diseases
EP3768706A1 (en) * 2018-03-23 2021-01-27 AbbVie Deutschland GmbH & Co. KG Stable aqueous anti-tau antibody formulations
EP3775267A4 (en) * 2018-04-10 2022-05-18 Askgene Pharma, Inc. NEW DUAL ANTAGONISTS OF VEGF AND ANGIOPOIETIN 2
WO2019217927A1 (en) 2018-05-10 2019-11-14 Regeneron Pharmaceuticals, Inc. High concentration vegf receptor fusion protein containing formulations
US10894824B2 (en) 2018-09-24 2021-01-19 Aerpio Pharmaceuticals, Inc. Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF
AR116566A1 (es) 2018-10-03 2021-05-19 Novartis Ag Administración sostenida de polipéptidos similares a la angiopoyetina 3
SG11202103670XA (en) * 2018-10-10 2021-05-28 Astellas Pharma Inc Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex
MX2021004774A (es) * 2018-10-29 2021-08-24 Hoffmann La Roche Formulacion de anticuerpos.
CA3119179A1 (en) 2018-11-07 2020-05-14 Applied Molecular Transport Inc. Cholix-derived carriers for oral delivery of heterologous payload
JOP20210152A1 (ar) * 2018-12-18 2023-01-30 Novartis Ag صياغة محلول بروتيني محتوية على تركيز عالٍ من جسم مضاد لـ vegf
CA3129901A1 (en) 2019-02-18 2020-08-27 Eli Lilly And Company Therapeutic antibody formulation
TW202106699A (zh) 2019-04-26 2021-02-16 美商愛德維仁生物科技公司 用於玻璃體內遞送之變異體aav蛋白殼
JP2022530657A (ja) 2019-04-29 2022-06-30 アイポイント ファーマシューティカルズ， インコーポレイテッド シュレム管を標的とするＴｉｅ－２活性化物質
MX2022001975A (es) 2019-08-16 2022-03-11 Applied Molecular Transport Inc Composiciones, formulaciones y produccion y purificacion de interleucinas.
WO2021072265A1 (en) * 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CN111217834B (zh) 2020-02-21 2021-10-26 维眸生物科技（上海）有限公司 Rock激酶抑制剂的硝基氧衍生物
CN113698478A (zh) * 2020-05-21 2021-11-26 迈威(上海)生物科技股份有限公司 抗α-溶血素的抗体及其稳定制剂
KR20220001106A (ko) * 2020-06-29 2022-01-05 (주)메디톡스 고농도 항-ｖｅｇｆ 항체 제제 및 이에 사용하기 위한 항-ｖｅｇｆ 항체
AU2021308712A1 (en) 2020-07-16 2023-02-02 Novartis Ag Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
KR20240008821A (ko) * 2021-05-17 2024-01-19 리제너론 파아마슈티컬스, 인크. 혈관신생성 눈 장애 치료를 위한 연장된 고용량 vegf 길항제 요법
CN113940997B (zh) * 2021-12-21 2022-04-08 迈威(上海)生物科技股份有限公司 一种双特异性抗体的稳定制剂
WO2024056058A1 (zh) * 2022-09-16 2024-03-21 齐鲁制药有限公司 一种稳定的高浓度自缓冲药物组合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP2319492A3 (en) * 2004-10-21 2011-08-10 Genentech, Inc. Method for treating intraocular neovascular diseases
WO2007011873A2 (en) * 2005-07-15 2007-01-25 Genentech, Inc. Method for treating intraocular neovascular diseases
JP5216002B2 (ja) * 2006-06-16 2013-06-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 硝子体内投与に適したｖｅｇｆアンタゴニスト製剤
CA3020290A1 (en) * 2008-06-25 2009-12-30 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting vegf
MX344076B (es) 2008-06-30 2016-12-05 Esbatech Alcon Biomed Res Unit Polipeptidos funcionalizados.
SG10201802789VA (en) * 2011-01-13 2018-05-30 Regeneron Pharma Use of a vegf antagonist to treat angiogenic eye disorders
SG194932A1 (en) * 2011-06-30 2013-12-30 Genentech Inc Anti-c-met antibody formulations
UY34404A (es) * 2011-10-20 2013-05-31 Esbatech A Novartis Co Llc Anticuerpo estable unido a múltiples antígenos
UA117466C2 (uk) * 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
WO2015086830A1 (en) * 2013-12-13 2015-06-18 Delenex Therapeutics Ag Skin penetrating polypeptides
TWI806150B (zh) 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
US20160144025A1 (en) 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases

Also Published As

Publication number Publication date
RU2017119647A (ru) 2018-12-07
IL283561A (he) 2021-07-29
TW202103735A (zh) 2021-02-01
CL2017001115A1 (es) 2018-01-26
CA2966758A1 (en) 2016-05-12
TWI806150B (zh) 2023-06-21
US11098110B2 (en) 2021-08-24
KR20230066649A (ko) 2023-05-16
AU2020220210B2 (en) 2022-01-20
JP2020193212A (ja) 2020-12-03
AU2018278870A1 (en) 2019-01-03
EP3215123A1 (en) 2017-09-13
EP3215122A1 (en) 2017-09-13
RU2020114917A (ru) 2020-05-22
IL265497B (he) 2021-06-30
PH12017500844B1 (en) 2017-10-30
US20200270336A1 (en) 2020-08-27
ECSP17034829A (es) 2019-02-28
JP2017538674A (ja) 2017-12-28
US10689438B2 (en) 2020-06-23
BR112017008093A2 (pt) 2018-03-13
JP7080263B2 (ja) 2022-06-03
JP2020079242A (ja) 2020-05-28
PH12017500843A1 (en) 2017-10-30
IL283561B (he) 2022-01-01
AU2020220210A1 (en) 2020-10-01
JP6667519B2 (ja) 2020-03-18
KR20170082526A (ko) 2017-07-14
TW201625306A (zh) 2016-07-16
AU2020244614B2 (en) 2023-06-01
TN2017000128A1 (en) 2018-10-19
RU2722643C2 (ru) 2020-06-02
CN114081951A (zh) 2022-02-25
WO2016073918A1 (en) 2016-05-12
US20180298092A1 (en) 2018-10-18
KR102588846B1 (ko) 2023-10-16
JP2017534638A (ja) 2017-11-24
PH12017500844A1 (en) 2017-10-30
NZ730821A (en) 2019-11-29
AU2015342815A1 (en) 2017-05-11
MY183807A (en) 2021-03-16
CO2017004596A2 (es) 2017-08-31
AU2018274882B2 (en) 2020-07-09
IL280087A (he) 2021-03-01
CL2017001117A1 (es) 2018-01-26
TW202146049A (zh) 2021-12-16
RU2020114917A3 (he) 2022-01-17
US10035850B2 (en) 2018-07-31
IL251642B (he) 2021-02-28
JP6753848B2 (ja) 2020-09-09
CN106999581A (zh) 2017-08-01
TWI705827B (zh) 2020-10-01
SG11201702954XA (en) 2017-05-30
PE20170780A1 (es) 2017-07-04
MY193913A (en) 2022-11-01
WO2016073915A1 (en) 2016-05-12
AU2018278870B2 (en) 2020-05-28
IL265497A (he) 2019-05-30
CA2966646A1 (en) 2016-05-12
CN107635580A (zh) 2018-01-26
TWI761959B (zh) 2022-04-21
EA201790989A1 (ru) 2017-09-29
IL251696A0 (he) 2017-06-29
SG10201913565RA (en) 2020-02-27
IL251642A0 (he) 2017-06-29
AU2020244614A1 (en) 2020-11-05
US20160130337A1 (en) 2016-05-12
GT201700096A (es) 2019-10-10
RU2017119647A3 (he) 2019-05-29
MX2017005874A (es) 2017-06-26
MX2021006768A (es) 2021-07-15
IL280087B (he) 2022-02-01
BR112017008660A2 (pt) 2017-12-26
MX2017005875A (es) 2017-06-26
AU2018274882A1 (en) 2018-12-20
TW201625221A (zh) 2016-07-16
US20210340242A1 (en) 2021-11-04
KR20170076781A (ko) 2017-07-04
US20160340420A1 (en) 2016-11-24
AU2015342815B2 (en) 2018-12-13
AU2015342818A1 (en) 2017-05-11
JP2022141923A (ja) 2022-09-29
AU2015342818B2 (en) 2019-01-03
TWI738632B (zh) 2021-09-11

Similar Documents

Publication Publication Date Title
IL280087B (he) פורמולציות יציבות של תמיסות חלבון המכילות ריכוז גבוה של נוגדן אנטי–vegf
HK1254198A1 (zh) 抗-vegf抗體的優化的變體
SG11202003754YA (en) High concentration protein formulations with reduced viscosity
SG11201706505PA (en) Stable liquid formulation for monoclonal antibodies
IL250363A0 (he) פורמולציה יציבה של נוגדן אנטי-il-4r-alpha
PT4023755T (pt) Moléculas de ácido nucleico artificiais para uma expressão melhorada de proteína
HRP20201107T8 (hr) Heteroaril amidi kao inhibitori proteinske agregacije
EA201690667A1 (ru) Композиции, содержащие антитело к pdl1
GB2541599B (en) Nucleic acid for coding chimeric antigen receptor protein and T lymphocyte for expression of chimeric antigen receptor protein
EP3177924A4 (en) Stabilization of whole blood samples
IL249395A0 (he) ניתוח כמותי של חלבונים טרנסגניים
HK1244445A1 (zh) 使用抗-ang2抗體的方法
EP3185004A4 (en) Method for measuring viscosity of protein solution
IL272934A (he) הרכבים רוקחיים המכילים מינון גבוה של פרידופידין
EA202091567A1 (ru) Химерные белки мти
IL279895A (he) פורמולציות של נוגדנים נוזליות בריכוז גבוה
IL283456A (he) פורמולציה של תמיסת חלבון המכילה ריכוזים גבוהים של נוגדן כנגד vegf
GB201412156D0 (en) Analyte concentration measurement
IL283229A (he) פורמולציה של חלבון בריכוז גבוה
ZA201708173B (en) High concentration formulation
IL251568A0 (he) חומרים אמינופירידינים יעילים כמעכבי פרנילציה בחלבונים
TH1701002455A (th) สูตรผสมของสารละลายโปรตีนที่เสถียรซึ่งมีความเข้มข้นที่สูงของแอนติบอดีต่อ vegf
GB201415425D0 (en) Small molecule inhibitors of classiv bromodomain proteins
FI20146113A (fi) Proteiinien konsentrointimenetelmä
TH1601002253A (th) สูตรผสมของอินซูลินกลูไลซีนที่คงตัว